Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis

• Main Authors: Giniatullina Raisa, Goldsteins Gundars, Ahtoniemi Toni, Wojciechowski Sara, Malm Tarja, Kanninen Katja, Jaronen Merja, Savchenko Ekaterina, Pollari Eveliina, Giniatullin Rashid, Koistinaho Jari, Magga Johanna
• Format: Article
• Language: English
• Published: BMC 2011-06-01
• Series: Journal of Neuroinflammation
• Subjects: Amyotrophic lateral sclerosis; GCSF; pegfilgrastim; inflammation; monocytes; cytokines
• Online Access: http://www.jneuroinflammation.com/content/8/1/74

<p>Abstract</p> <p>Background</p> <p>Granulocyte colony stimulating factor (GCSF) is protective in animal models of various neurodegenerative diseases. We investigated whether pegfilgrastim, GCSF with sustained action, is protective in a mouse model of amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease with manifestations of upper and lower motoneuron death and muscle atrophy accompanied by inflammation in the CNS and periphery.</p> <p>Methods</p> <p>Human mutant G93A superoxide dismutase (SOD1) ALS mice were treated with pegfilgrastim starting at the presymptomatic stage and continued until the end stage. After long-term pegfilgrastim treatment, the inflammation status was defined in the spinal cord and peripheral tissues including hematopoietic organs and muscle. The effect of GCSF on spinal cord neuron survival and microglia, bone marrow and spleen monocyte activation was assessed <it>in vitro</it>.</p> <p>Results</p> <p>Long-term pegfilgrastim treatment prolonged mutant SOD1 mice survival and attenuated both astro- and microgliosis in the spinal cord. Pegfilgrastim in SOD1 mice modulated the inflammatory cell populations in the bone marrow and spleen and reduced the production of pro-inflammatory cytokine in monocytes and microglia. The mobilization of hematopoietic stem cells into the circulation was restored back to basal level after long-term pegfilgrastim treatment in SOD1 mice while the storage of Ly6C expressing monocytes in the bone marrow and spleen remained elevated. After pegfilgrastim treatment, an increased proportion of these cells in the degenerative muscle was detected at the end stage of ALS.</p> <p>Conclusions</p> <p>GCSF attenuated inflammation in the CNS and the periphery in a mouse model of ALS and thereby delayed the progression of the disease. This mechanism of action targeting inflammation provides a new perspective of the usage of GCSF in the treatment of ALS.</p>